Friday, October 10, 2025 10/10/2025

Cellular and Molecular Control of Normal and Disordered Erythropoiesis

Award Number: R35HL171168
ORGANIZATION: NATIONAL HEART, LUNG, & BLOOD INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 02/15/2024
PERIOD OF PERFORMANCE END DATE: 01/31/2031

Group Awards By:

View Award Description

Cellular and Molecular Control of Normal and Disordered Erythropoiesis - Project Summary/Abstract Red cell disorders affect more than 1 billion people worldwide, are a significant cause of morbidity and mortality and lead to a substantial economic burden. These disorders can result from a decrease in survival or in production (or both). Our research is focused on erythropoiesis and how this process goes awry in disorders such as Diamond Blackfan anemia (SCD), sickle cell disease (SCD) and anemia of inflammation. Our work has highlighted differences between neonatal and adult human erythropoiesis and used these findings to reveal the mechanism of steroid resistance in DBA. In parallel, we studied the mechanism of action of immunomodulatory drugs during erythropoiesis and how they increase fetal hemoglobin production in SCD. We recently identified the nature of the erythroblastic island in normal erythropoiesis and under inflammatory conditions. Together, these discoveries have allowed for a better understanding of normal and disordered erythropoiesis. Nevertheless, critical basic and translational questions remain in DBA and SCD. The proposed research program builds upon Dr. Blanc’s productive research track record to determine (i) why the erythropoietic defect in DBA manifests after birth, (ii) how the erythroblastic island in the bone marrow contributes to the pathophysiology of DBA and SCD and (iii) identifying new targets and treatments for DBA and SCD. To answer these questions, we propose an ambitious research program divided into three projects. The first will investigate the impact of differential regulation of ribosome biogenesis and cell cycle length in fetal versus adult erythropoiesis. The second will address the contribution of the newly characterized erythromyeloblastic island to the pathophysiology of DBA and SCD and the third will focus on identifying and testing new drugs for the treatment of these two hematologic disorders. As a whole this program should (i) offer new models to study ribosomal protein biology relevant to heart and blood disorders, (ii) explain how the erythroid niche universally contributes to inflammation in hematologic disorders and (iii) offer new therapies for the treatment of bone marrow failure syndromes and sickle cell disease.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = $870,543 )
2025	2025	THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH	350 COMMUNITY DR	MANHASSET	NY	11030	NASSAU	USA	Blood Diseases and Resources Research	001	2	8/26/2025	NON-COMPETING CONTINUATION	$17,411
2025	2025	THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH	350 COMMUNITY DR	MANHASSET	NY	11030	NASSAU	USA	Blood Diseases and Resources Research	000	2	1/28/2025	NON-COMPETING CONTINUATION	$853,132
														Subtotal = $870,543

Issue Date FY: 2024 ( Subtotal = $870,543 )
2024	2024	FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH, THE	350 COMMUNITY DR	MANHASSET	NY	11030	NASSAU	USA	Blood Diseases and Resources Research	000	1	2/6/2024	NEW	$870,543
														Subtotal = $870,543

Grand Total All Awards = $1,741,086

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Cellular and Molecular Control of Normal and Disordered Erythropoiesis

Award Number: R35HL171168

ORGANIZATION: NATIONAL HEART, LUNG, & BLOOD INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 02/15/2024

PERIOD OF PERFORMANCE END DATE: 01/31/2031

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer